Home page News Related Researches 2010-2019

A role of somatostatin analogues in the treatment of patients with hormone-refractory prostate cancer

Published on Tuesday, 25 August 2026

Abstract

Prostate cancer (PC) is one of the most pressing problems of urologic cancer due to higher morbidity from this pathology worldwide. Treatment policy in PC patients is determined by the extent of a cancer process. Radical therapy for metastatic PC is impossible, hence this patient group is considered eligible for palliative hormonal or chemotherapy.

To choose the optimal treatment for patients with hormone-refractory PS (HRPS) is an intricate problem regarding particularly patients with asymptomatic HRPS and those with progressive cancer after chemotherapy with docetaxel. In this instance, the treatment policy is a matter of discussion and is not well defined.

The paper considers the use of somatostatin analogues as an alternative to drug therapy for patients with HRPS. Octreotide is one of the most popular drugs of this group. The agent may be used to treat patients with HRPS both before and after systemic cytotoxic therapy.

Octreotide therapy is effective and safe; its side effects are minimal and it is well tolerated in patients.

Download the complete article

About this publication.

The Di Bella's Method: Use of Somatostatin/Octreotide analogues and/or derivatives (since 1977), Retinoic Acid, Beta-Carotene and Axerophthol palmitate, Hormone therapy (e.g. Enantone, Decapeptyl and analogues), Melatonin (since 1974), pseudo-Metronomic Chemotherapy Cyclophosphamide and/or Hydroxyurea with prolactin inhibitors Cabergoline and/or Bromocriptine (together with others chemical compounds) in Prostate Cancer (the dosage and administration schedule must be individualised for each patient):

- Disease Control after Androgen Deprivation Therapy Combined with Di Bella Multitherapy (Di Bella's Foundation);

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives since 1977);

- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;

- Publication, 2018 Jul: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);

- Publication, 2018 Sep: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature (from Di Bella's Foundation);

- Publication, 2019 Aug: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);

- Publication, 2019 Sep: Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes (from Di Bella's Foundation);

- Publication, 2019 Sep: Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes (from Di Bella's Foundation);

- Publication, 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (from Di Bella's Foundation);

- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);

- Prolactin inhibitors in oncology - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Cyclophosphamide 50mg tablets and/or Hydroxyurea 500mg tablets, one or two per day);

The Di Bella's Method: Use of Somatostatin/Octreotide analogues and/or derivatives since 1977, prolactin inhibitors Cabergoline and/or Bromocriptine associated with pseudo-Metronomic Chemotherapy Cyclophosphamide and/or Hydroxyurea - together with others chemical compounds: the dosage and administration schedule must be individualised for each patient - in several Oncological Pathologies:

- A retrospective observational study on cases of Osteosarcomas treated with a multitherapy: The rationale and effectiveness;

- A Retrospective Observational Study on Cases of Sarcoma Treated with the Di Bella Method: Rationale and Effectiveness;

- Congenital fibrosarcoma in complete remission with Somatostatin, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up;

- A retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary data;

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;